Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain
Deepti Navaratna, … , Xiaoying Wang, Eng H. Lo
Deepti Navaratna, … , Xiaoying Wang, Eng H. Lo
Published July 15, 2013
Citation Information: J Clin Invest. 2013;123(8):3373-3377. https://doi.org/10.1172/JCI65767.
View: Text | PDF
Brief Report Neuroscience Article has an altmetric score of 11

Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain

  • Text
  • PDF
Abstract

Diabetes elevates the risk for neurological diseases, but little is known about the underlying mechanisms. Brain-derived neurotrophic factor (BDNF) is secreted by microvascular endothelial cells (ECs) in the brain, functioning as a neuroprotectant through the activation of the neurotrophic tyrosine kinase receptor TRKB. In a rat model of streptozotocin-induced hyperglycemia, we found that endothelial activation of MMP9 altered TRKB-dependent trophic pathways by degrading TRKB in neurons. Treatment of brain microvascular ECs with advanced glycation endproducts (AGE), a metabolite commonly elevated in diabetic patients, increased MMP9 activation, similar to in vivo findings. Recombinant human MMP9 degraded the TRKB ectodomain in primary neuronal cultures, suggesting that TRKB could be a substrate for MMP9 proteolysis. Consequently, AGE-conditioned endothelial media with elevated MMP9 activity degraded the TRKB ectodomain and simultaneously disrupted the ability of endothelium to protect neurons against hypoxic injury. Our findings demonstrate that neuronal TRKB trophic function is ablated by MMP9-mediated degradation in the diabetic brain, disrupting cerebrovascular trophic coupling and leaving the brain vulnerable to injury.

Authors

Deepti Navaratna, Xiang Fan, Wendy Leung, Josephine Lok, Shuzhen Guo, Changhong Xing, Xiaoying Wang, Eng H. Lo

×

Figure 2

TRKB is degraded by MMP9.

Options: View larger image (or click on image) Download as PowerPoint
TRKB is degraded by MMP9.
(A) Representative low-resolution (upper row) ...
(A) Representative low-resolution (upper row) and high-resolution (lower row) TRKB immunohistochemistry showing neuronal TRKB signals in normal brains, decreased TRKB in 6-week diabetic rat brain, and decreased TRKB in MMP9-treated normal brain sections. Scale bars: 10 μm. (B) Representative Western blot showing increased levels of an approximately 25-kDa fragment in whole-brain extracts from diabetic rats. (C) Densitometric quantitation showing that 25-kDa fragments are significantly higher in 6- and 12-week diabetic rat cortex. *P < 0.05 between control and diabetic rat cortices; n = 4 per group. Error bars indicate SEM. (D) rhMMP9 cleaves TRKB/Fc to generate an approximately 25-kDa fragment along with a reduction in the full-length protein. Treatment with heat-inactivated (ht) rhMMP9 or rhMMP7 (0–1 μg/ml) does not generate a similar fragment. (E) Conditioned medium (CM) from AGE-stressed ECs (Endo) degrades TRKB/Fc, and this activity was blocked by the MMP inhibitor BB-94. (F) rhMMP9 degrades the TRKB T1 isoform in primary mouse embryonic neuronal cell extracts to a similar fragment in a dose-dependent manner (0–1 μg/ml). (G) rhMMP9 degrades the TRKB T1 ectodomain in live primary neurons in a dose-dependent manner (0–5 μg/ml).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Posted by 1 X users
32 readers on Mendeley
1 readers on CiteULike
See more details